The data from these studies will guide doctors in deciding whether sublingual semaglutide is a good option for their patients
The pivotal trials leading to FDA approval demonstrated reductions in visceral adipose tissue of approximately 15 to 20% over 26 weeks in HIV lipodystrophy patients, with continued reduction at 52 weeks
: , , As hopeful as this is, a few big questions remain, especially if we care about equity and not just headlines: - Will oral GLP-1s actually be covered by insurers and employers as long term therapy, instead of short weight loss sprints followed by predictable regain - How will pricing and step edits work when a patient has already been on an injectable for more than a year - Will these trials and future studies meaningfully include the diverse, underrepresented communities that carry a disproportionate burden of obesity, sleep apnea, and cardiometabolic disease : - Set expectations early: discuss obesity as chronic disease, and proactively plan for maintenance before stopping anything
We will have a thorough consultation to discuss your medical history, family history, social history, surgical history, current medications, and your current lifestyle and goals
Visit our top recommended supplier to obtain high-purity epithalon for research
He's a dead man
